Novo Nordisk’s strategy is best understood as a study in sustained specialization. The company has remained close to a defined set of medical problems while repeatedly changing its research, products, and organization to meet new technical and competitive pressures.
That combination offers a useful playbook for founders, product leaders, and executives. It also comes with a warning: focus works only when a company remains willing to replace the methods that produced its earlier success.
Verdict: a focused business designed for long horizons
Novo Nordisk stands out as a strong case study in compounding expertise. Its most instructive choices were not flashy expansions into unrelated markets. They involved applying existing knowledge to adjacent problems, turning complicated treatments into more usable products, and creating an ownership structure that supports decisions beyond the next reporting period.
The model is most relevant to organizations operating in technically demanding markets where research, manufacturing, and trust take years to develop. It is less suitable as a universal formula. Deep specialization can become tunnel vision, while protection from short-term pressure can weaken accountability if leadership lacks discipline.
How adaptation became part of the strategy
The development of synthetic human insulin placed pressure on older animal-derived production methods during the 1970s. The strategic lesson is straightforward: expertise in an established technology does not protect a company when the underlying technology changes. It may instead increase the cost of letting go.
Novo and Nordisk merged in 1989, bringing two competing Danish businesses together as Novo Nordisk. The combined company retained diabetes as a central area while extending its work into related fields such as obesity and other chronic conditions.
Early GLP-1 research also demonstrated the value of paying attention to unexpected results. Experiments included material extracted from pig pancreases and tests involving diabetic pigs. When later human testing produced an apparent reduction in appetite, the observation suggested possibilities beyond the experiment’s immediate objective. It did not amount to a finished product, but it illustrated how an adjacent finding can redirect a research program.
The broader point is not that every surprising laboratory result becomes a business. It is that focused companies still need systems for recognizing discoveries that fall outside the original hypothesis.
Five lessons for product and business leaders
- Borrow ideas from outside the category. The NovoPen drew inspiration from familiar objects such as ballpoint pens and mechanical pencils. That design approach reframed insulin delivery as an everyday usability problem rather than only a medical-engineering challenge.
- Build depth before chasing breadth. Staying close to diabetes gave the business a base of scientific and operational knowledge that could be applied to neighboring metabolic-health problems. The tradeoff is concentration, so specialization must be paired with continuous technical adaptation.
- Make the mission operational. A corporate purpose has little value if it appears only in branding. It becomes useful when it guides research priorities, product decisions, and the boundaries around expansion.
- Treat retention as a strategic capability. During difficult periods, former CEO Mads Øvlisen favored relocating employees within the company instead of defaulting to layoffs. That approach treated accumulated knowledge as an asset worth preserving, although it also required management to find productive roles rather than merely protecting headcount.
- Match ownership to the desired time horizon. A foundation holds controlling shares in Novo Nordisk, giving the company room to consider longer-term outcomes. Such a structure can reduce pressure for immediate returns, but it works only when governance still demands clear results and responsible execution.
None of these practices is unique to pharmaceuticals. Together, however, they explain why the Novo Nordisk model remains relevant: concentrate expertise, keep redesigning the delivery mechanism, preserve institutional knowledge, and give long-term projects enough time to prove themselves.